Cancer Immunotherapy Clinic

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Ce...

TIICs will be analyzed by immunohistochemistry (IHC) in pre- and post-pembrolizumab-based treatment tumor specimens. The proportion of participants with a >=2-fold increase (from pre- to post-treatment) in the number of TIICs will...

Recruiting

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refrac...

Treatment-related Adverse events resulting in a DLT will be summarized by maximum toxicity grade for each dose level of isatuximab.

Recruiting

A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants Wit...

Recruiting

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in ...

Dose limiting toxicity (DLT) is defined as protocol-defined adverse events that occur within 28 days following infusion of Neo-TCR-P1 administered as a single agent without or with IL-2, or in combination with nivolumab.

Recruiting

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Adv...

Recruiting

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...

Incidence of adverse events (AEs) observed across STRO-001 dose levels

Recruiting

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Only patients in cohort 2, who achieve testosterone recovery to non-castrate levels (>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA < nadir + 2 ng/mL at 15 months from the start of radiotherap...

Recruiting

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...

ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...

Recruiting

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Infor...

Recruiting

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Da...

Radiographic progression free survival (rPFS) is defined as the time from the first day of study treatment with pembrolizumab to the date of documented radiographic tumor progression or death due to any cause, whichever occurs fir...

Recruiting